Adele Fielding

From Wikipedia, the free encyclopedia
Adele Kay Fielding
Alma materUniversity of London
University College London
Scientific career
InstitutionsMayo Clinic
Royal Free Hospital
University College London Hospitals NHS Foundation Trust
University College London
ThesisTargeting fusogenic retroviral glycoproteins by ligand display. (1999)

Adele Kay Fielding is a British physician who is a Professor of Haematology at University College London. Fielding was elected President of the British Society for Haematology in 2020.[1]

Early life and education[]

Fielding was a medical student at University College London.[2] She was a trainee in haematology and general medicine in London. She moved to the Medical Research Council laboratory in Cambridge for her doctoral research, and completed her doctorate in 1999.[3][4]

Research and career[]

In 1999, Fielding was appointed assistant professor at the Mayo Clinic.[4] She returned to the United Kingdom in 2003, where she joined the Royal Free Hospital. She eventually moved to the University College London Hospitals NHS Foundation Trust, where she works in leukemia. Specifically, her research efforts look to improve the lives of people with acute lymphoblastic leukemia (ALL).[5] She is part of several clinical trials into ALL, which include studying the underlying mechanisms and searching for new treatments.[6] Fielding has developed an attenuated oncolytic measles virus that can be used as a treatment of ALL.[2]

Fielding was elected President of the British Society for Haematology in 2020.[1][7]

Selected publications[]

  • Hagop Kantarjian; Anthony Stein; Adele K Fielding; et al. (1 March 2017). "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia". The New England Journal of Medicine. 376 (9): 836–847. doi:10.1056/NEJMOA1609783. ISSN 0028-4793. PMC 5881572. PMID 28249141. Wikidata Q40312849.
  • Adele K Fielding; Susan M Richards; Rajesh Chopra; et al. (10 October 2006). "Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study". Blood. 109 (3): 944–950. doi:10.1182/BLOOD-2006-05-018192. ISSN 0006-4971. PMID 17032921. Wikidata Q43889424.
  • Max S Topp; Nicola Gökbuget; Anthony S Stein; et al. (16 December 2014). "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study". Lancet Oncology Commission. 16 (1): 57–66. doi:10.1016/S1470-2045(14)71170-2. ISSN 1470-2045. PMID 25524800. Wikidata Q34042800.

References[]

  1. ^ a b "A message from BSH President, Professor Adele Fielding - July 2020 | British Society for Haematology". b-s-h.org.uk. Retrieved 2021-07-20.
  2. ^ a b "Professor Adele Fielding : University College London Hospitals NHS Foundation Trust". www.uclh.nhs.uk. Retrieved 2021-07-20.
  3. ^ Fielding, Adele Kay (1999). Targeting fusogenic retroviral glycoproteins by ligand display (Thesis).
  4. ^ a b "Dr Adele Fielding – At the Limits". Retrieved 2021-07-20.
  5. ^ UCL (2017-12-19). "Biology of Adult Lymphoblastic Leukaemia and Oncolytic Virus Therapy Research Group". UCL Cancer Institute. Retrieved 2021-07-20.
  6. ^ "Professor Adele Fielding". Cancer Research UK. 2017-02-06. Retrieved 2021-07-20.
  7. ^ "Board of Trustees | British Society for Haematology". b-s-h.org.uk. Retrieved 2021-07-20.

External links[]

Retrieved from ""